CStone Pharmaceuticals

Company snapshot

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully laun

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CStone Pharmaceuticals. Not investment advice.

• approval Jun 6, 2026

  Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

• What is CStone Pharmaceuticals?

  Cstone Pharmaceuticals Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include Advanced Refractory Solid Tumors. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Clinic

• Is CStone Pharmaceuticals publicly traded?

  CStone Pharmaceuticals appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does CStone Pharmaceuticals develop or market?

  We link 1 drug profile(s) where CStone Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cstone-pharmaceuticals-ireland-limited#company-drugs.

• What are the latest developments for CStone Pharmaceuticals?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CStone Pharmaceuticals focus on?

  CStone Pharmaceuticals focuses on Advanced Refractory Solid Tumors based on our analysis of their pipeline programs and drug development activities.